Eli Lilly and Company (LLY)vsWarby Parker Inc (WRBY)
LLY
Eli Lilly and Company
$1,131.42
-0.26%
HEALTHCARE · Cap: $948.95B
WRBY
Warby Parker Inc
$22.72
-5.80%
HEALTHCARE · Cap: $3.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 8013% more annual revenue ($72.25B vs $890.57M). LLY leads profitability with a 35.0% profit margin vs 0.1%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
WRBY
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-50.4%
Fair Value
$14.62
Current Price
$22.72
$8.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
ROE of 0.4% — below average capital efficiency
0.1% margin — thin
Operating margin of 0.9%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : WRBY
WRBY has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : WRBY
The primary concerns for WRBY are Return on Equity, Profit Margin, Operating Margin. A P/E of 2479.0x leaves little room for execution misses. Thin 0.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 1.96 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 31/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. (WRBY) is a trendsetting leader in the direct-to-consumer eyewear market, established in 2010 with the mission to revolutionize the way consumers purchase eyewear through a seamless blend of online shopping and an expanding number of retail stores. The company is renowned for its stylish, affordable prescription glasses and sunglasses, appealing to a broad range of customers. Warby Parker's socially conscious business model, epitomized by its "Buy a Pair, Give a Pair" initiative, reflects a commitment to social responsibility by providing eyewear to those in need. With a robust brand reputation and a dedication to innovative marketing strategies, Warby Parker is well-positioned for ongoing growth and success in a competitive landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?